Global drug development requires coordinated execution across scientific strategy, clinical sites, data management, patient safety, regulatory requirements, and project delivery. A full-service contract research organization (CRO) can bring these functions together within a coordinated operating model, while drawing on specialist support where appropriate.

This article introduces eight established providers with broad clinical development capabilities. The selection considers service scope, multinational delivery, lifecycle coverage, and relevance to different sponsor needs. It is intended as a general industry reference rather than a ranking or comparative assessment.

What Defines a Full-Service CRO?

Under a full-service outsourcing model, a CRO performs or coordinates most or all agreed study activities through an integrated delivery structure. Depending on the program, the scope may include protocol development support, study start-up, site management, clinical monitoring, biometrics—including data management, biostatistics, and statistical programming—medical writing, pharmacovigilance, regulatory submissions, and study closeout. The sponsor nevertheless retains ultimate responsibility for its trial-related activities, including the protection of participants’ rights, safety, and well-being and the reliability of trial data.

The appropriate model depends on the asset, development phase, geographic scope, and sponsor organization. Emerging biotechnology companies may require close scientific collaboration, flexible resourcing, and turnkey end-to-end management from early-stage translational research through clinical proof of concept, while larger pharmaceutical companies may place greater emphasis on portfolio governance, standardized systems, and consistent delivery across multiple countries.

Sponsors should therefore assess not only the breadth of a provider’s service portfolio, but also its contracting structure, local delivery model, quality oversight, use of subcontractors, and allocation of responsibilities.

▶ Tigermed

▶ IQVIA

▶ PPD

▶ ICON plc

▶Parexel

▶Syneos Health

▶Fortrea

▶Medpace

Learn more about the concept of CROs: What Is a CRO? Contract Research Organizations & Clinical Research Organizations

1. Tigermed

Tigermed provides comprehensive, integrated full-service solutions spanning the entire drug development lifecycle, including preclinical research, laboratory testing, clinical development, regulatory affairs, site and participant management, and post-market research.

CRO Services offered by Tigermed

With its Global Headquarters in Hangzhou and International Headquarters in Hong Kong, Tigermed combines its Asia-Pacific presence with global operations. The company is dual-listed on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange, forming an “A+H” capital-market platform.

As of June 30, 2026, Tigermed had 11,984 employees across 43 countries and 667 ongoing drug clinical research projects, including 264 ongoing overseas projects. During the same period, Tigermed had provided services for 210 approved Class 1 innovative drugs in China, representing 62% of all such drugs approved in China. According to Frost & Sullivan data cited in Tigermed’s 2026 Interim Results, Tigermed maintained its leading position in China’s clinical CRO market in 2025, with a market share of 10.9%, and remained the only Chinese clinical CRO ranked among the global Top 10.

For international sponsors developing products, Tigermed supports early-stage development, regulatory registration, and investigator-initiated trials, while coordinating these activities with broader global programs. Its integrated service model is complemented by digital capabilities in decentralized clinical trials and AI-supported workflows. These include tools for medical writing, regulatory submissions, biostatistics, translation, and pharmacovigilance, together with continued investment in DCT research and clinical trial AI applications.

Tigermed Global Principal Office Locations

2. IQVIA

IQVIA combines clinical development services with healthcare data, analytics, and technology. Its research and development portfolio includes early-phase studies, Phase IIb and III trials, patient and site services, functional services, global laboratories, and R&D consulting.

The company also provides services in real-world evidence, safety, and regulatory compliance. Through IQVIA Biotech, it supports emerging biopharmaceutical companies from early development through global registration programs.

3. PPD, Part of Thermo Fisher Scientific

The PPD clinical research business provides services across early development, all phases of clinical research, and peri-approval and post-approval programs. Its capabilities include patient recruitment, investigator and site support, clinical operations, and laboratory services.

PPD offers both full-service and functional service partnership models. As part of Thermo Fisher Scientific, it can also connect clinical trial delivery with a broader range of laboratory and analytical capabilities. Its service portfolio supports pharmaceutical, biotechnology, medical device, and government organizations.

4. ICON plc

ICON provides clinical development and commercialization services across Phase I to IV studies. Its capabilities include consulting, study operations, site and patient access, functional services, and decentralized or hybrid trial delivery.

The company supports both locally focused studies and multinational development programs. Its operating profile identifies full-service Phase II and III research and services for biotechnology sponsors among its core areas.

5. Parexel

Parexel provides Phase I to IV clinical development services through an integrated portfolio covering early development, clinical operations, regulatory strategy and submissions, real-world evidence, market access, and lifecycle management.

Its services support a range of therapeutic areas and development approaches, including oncology, neuroscience, immunology, rare diseases, and cell and gene therapies. The company’s global service portfolio may be relevant to sponsors seeking regulatory and market-access expertise alongside clinical trial delivery.

6. Syneos Health

Syneos Health combines full-service clinical development with functional service partnerships and commercial capabilities. Its clinical development services cover early-phase research, Phase II to IV studies, real-world evidence, study start-up, patient recruitment, safety, regulatory affairs, bioanalysis, biometrics, and decentralized or hybrid trials.

Its operating model is designed to connect clinical development with medical affairs and commercialization planning. This may be relevant to sponsors considering development and commercialization requirements within a coordinated framework.

7. Fortrea

Fortrea provides Phase I–IV clinical trial management, clinical pharmacology, and market access solutions through full-service outsourcing, functional service provider, and hybrid delivery models. Its capabilities support both focused proof-of-concept studies and larger multinational programs.

Fortrea completed its spin-off from Labcorp in 2023 and now operates as an independent CRO providing clinical development and patient access solutions. Its global operating network and dedicated early-phase clinical research units support studies requiring execution across multiple regions.

8. Medpace

Medpace is a global full-service CRO supporting Phase I–IV clinical studies. Its integrated operating model includes wholly owned central and bioanalytical laboratories, imaging and ECG core laboratories, a Phase I unit, and its proprietary ClinTrak clinical trial management system.

The model is structured around cross-functional coordination throughout the study lifecycle. Medpace serves biotechnology, pharmaceutical, and medical device sponsors across a range of therapeutic areas.

How to Evaluate Full-Service CROs

A CRO shortlist should begin with the requirements of the protocol and development program rather than company size alone. When evaluating full-service partners specifically, sponsors should assess:

· End-to-End Lifecycle Integration and Scope Continuity: The ability to support preclinical testing, early clinical pharmacology, Phase I–IV multicenter studies, and post-marketing research under unified project governance, reducing the risks and administrative burden associated with multiple vendor handoffs.

· Scientific and Development-Phase Alignment: Therapeutic-area expertise, study design capabilities, and experience with the relevant product modality, development stage, and clinical endpoints.

· Site Access and Patient Recruitment Capabilities: Access to hospital and site networks, Phase I research resources, and dedicated site management organization (SMO) teams and clinical research coordinators (CRCs) to support timely site activation and patient enrollment in key markets.

· Geographic Coverage and Local Execution: Local teams, site relationships, regulatory knowledge, language capabilities, and cross-border data-management processes across relevant regions.

· Delivery Model and Accountability: Clear allocation of responsibilities under full-service, functional service provider (FSP), or hybrid arrangements, with defined escalation pathways, cross-functional coordination, and team continuity.

· Quality Systems and Technology Capabilities: Quality management systems, regulatory inspection experience, validated systems, cybersecurity controls, data-integrity practices, and appropriate human oversight of AI-supported workflows.

· Commercial Transparency and Governance: Clear budget and timeline assumptions, pass-through costs, change-control procedures, contractual governance, and sponsor access to relevant operational data.

No single operating model is appropriate for every development program. Sponsors should evaluate each provider against the scientific, operational, regulatory, geographic, and commercial requirements of the specific study.

For programs connecting China with other markets, Tigermed combines experience in China’s clinical and regulatory environment with local international teams, integrated services, and coordinated global delivery.

Learn more about CRO services and how to choose the right CRO partner: What Are CRO Services and How to Choose the Right CRO Company?

Conclusion

A CRO partner that is highly aligned with the specific needs of a development program can help sponsors optimize research processes, improve operational efficiency, reduce execution risks, and support the successful advancement of innovative products from clinical development through regulatory approval and commercialization.

For sponsors seeking to accelerate global clinical development, Tigermed leverages its global operational network, integrated clinical service capabilities, and extensive cross-regional development experience to provide tailored solutions. To learn more about global clinical development services, please contact the Tigermed team for further discussion.

* Disclaimer

All company names, trademarks, and logos mentioned in this article are the property of their respective owners. This article is provided for general informational and industry reference purposes only and does not constitute an official ranking, endorsement, recommendation, or evaluation of any CRO provider.

The companies mentioned in this article are included solely for industry discussion and reference purposes. The inclusion and order of these companies do not represent a ranking or comparison of their performance, service quality, capabilities, or market position, nor do they imply any affiliation, partnership, or commercial relationship with Tigermed.

The information presented in this article is based on publicly available sources at the time of publication and may change over time. This article does not constitute medical, scientific, regulatory, legal, procurement, financial, or investment advice. Sponsors should independently verify each provider’s current capabilities, qualifications, compliance status, service availability, and commercial terms, and conduct appropriate due diligence based on their specific needs before selecting a CRO partner.